Genmab A/S (GNMSF) Stock Price, News & Analysis

Company Overview

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, the company operates research and development facilities across Europe and maintains a global presence through strategic partnerships. Over two decades, Genmab has transitioned from a regional biotech start-up into a fully integrated R&D-driven organization with a focus on advancing novel antibody formats and immuno-oncology solutions.

At the core of Genmab’s innovation is its proprietary antibody platforms, including the DuoBody® bispecific technology and HexaBody® Fc-enhanced platform, which enable the creation of multi-specific and high-potency antibody candidates. The company’s pipeline encompasses a broad array of clinical- and preclinical-stage molecules targeting hematologic malignancies, solid tumors, and autoimmune conditions. Genmab’s collaborative agreements with leading pharmaceutical companies, such as Janssen and Novartis, have yielded several approved therapies, including ofatumumab-based treatments and daratumumab products, underscoring its ability to translate early-stage research into commercially successful medicines.

Genmab serves patients worldwide through its partnerships and sublicensees, with a particular focus on markets in North America, Europe and Asia-Pacific. The company leverages a hybrid model that combines in-house expertise in antibody design, process development and regulatory affairs with the global reach of strategic collaborators. Under the leadership of CEO David L. Junio and an experienced executive team, Genmab continues to expand its pipeline, invest in next-generation antibody technologies and pursue regulatory approvals for novel therapies. This sustained focus on innovation and collaboration positions Genmab as a notable player in the competitive landscape of biopharmaceutical R&D.

Key Stats

• Today's Range: $219.00 to $219.75
• 50-Day Range: $188.80 to $224.30
• 52-Week Range: $170.00 to $292.80
• Volume: 58 shs
• Average Volume: 35 shs
• Market Capitalization: $14.52 billion
• P/E Ratio: 12.46
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Genmab A/S Stock Analysis - MarketRank™

Genmab A/S scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Genmab A/S.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Genmab A/S is 12.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.51.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genmab A/S is 12.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.10.

Price to Book Value per Share Ratio

Genmab A/S has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.13% of the float of Genmab A/S has been sold short.

Short Interest Ratio / Days to Cover

Genmab A/S has a short interest ratio ("days to cover") of 833, which indicates bearish sentiment.

Change versus previous month

Short interest in Genmab A/S has recently increased by 86.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genmab A/S does not currently pay a dividend.

Dividend Growth

Genmab A/S does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.13% of the float of Genmab A/S has been sold short.

Short Interest Ratio / Days to Cover

Genmab A/S has a short interest ratio ("days to cover") of 833, which indicates bearish sentiment.

Change versus previous month

Short interest in Genmab A/S has recently increased by 86.35%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Genmab A/S has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Genmab A/S this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genmab A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.54% of the stock of Genmab A/S is held by insiders.

GNMSF Stock Analysis - Frequently Asked Questions

How have GNMSF shares performed this year?

Genmab A/S's stock was trading at $207.38 at the start of the year. Since then, GNMSF stock has increased by 6.0% and is now trading at $219.75.

How were Genmab A/S's earnings last quarter?

Genmab A/S (OTCMKTS:GNMSF) released its quarterly earnings data on Thursday, May, 8th. The company reported $3.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $1.17. The firm earned $765.14 million during the quarter, compared to the consensus estimate of $761.09 million. Genmab A/S had a net margin of 35.11% and a trailing twelve-month return on equity of 19.23%.

How do I buy shares of Genmab A/S?

Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/17/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:GNMSF
• CIK: 1434265
• Web: www.genmab.com
• Phone: (457) 020-2728
• Fax: 45-7020-2729
• Employees: 2,682
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): $17.63
• Trailing P/E Ratio: 12.46
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $1.14 billion
• Net Margins: 35.11%
• Pretax Margin: 40.96%
• Return on Equity: 19.23%
• Return on Assets: 15.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.34
• Quick Ratio: 5.32

Sales & Book Value

• Annual Sales: $3.12 billion
• Price / Sales: 4.65
• Cash Flow: $15.53 per share
• Price / Cash Flow: 14.15
• Book Value: $80.53 per share
• Price / Book: 2.73

Miscellaneous

• Outstanding Shares: 66,070,000
• Free Float: 65,057,000
• Market Cap: $14.52 billion
• Optionable: Not Optionable
• Beta: 0.91